Eloxx Pharmaceuticals, Inc. cash flow to debt ratio of 0.00% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Eloxx Pharmaceuticals, Inc.'s latest filing, so interest coverage cannot be calculated.

Eloxx Pharmaceuticals, Inc.'s profit margin has increased (-100.00%) in the last year from -49.43% to 0.00%, signaling increasing performance

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Eloxx Pharmaceuticals, Inc.'s return on equity of -42.52%, is lower than 15.00%, indicating bad performance

Eloxx Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate earnings stability.

Eloxx Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Eloxx Pharmaceuticals, Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Eloxx Pharmaceuticals, Inc.'s yearly earnings has decreased 90.74% since last year from $-3.14M to $-6.00M, signaling decreasing performance

Eloxx Pharmaceuticals, Inc.'s yearly revenue has decreased 100.00% since last year from $6.36M to $0.00, signaling decreasing performance

ROIC -17.76% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Eloxx Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate revenue consistency.

Eloxx Pharmaceuticals, Inc. has insufficient public price history to evaluate ROE consistency.

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Eloxx Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Eloxx Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Eloxx Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Eloxx Pharmaceuticals, Inc. has a price-to-book ratio of 2.08x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Eloxx Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue